 
		
		Shares of micro-cap company GeoVax, which specializes in cancer treatments and vaccines, rose nearly 7% on Wednesday, January 15. The company announced “significant progress” in early testing of its cancer drug for head and neck cancer and confirmed plans to move to the next phase of clinical trials. Analysts see…
 
			 
		 
			 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		 
		